Interpretation of Clinical Guidelines for the management of Rifampicin-resistant Tuberculosis in South Africa (2019) and its comparison with Guidelines for Drug-resistant Tuberculosis Chemotherapy in China (2019)

doi:10.3969/j.issn.1000-6621.2021.03.018

Abstract

Abstract:

To interpret the Clinical Guidelines for the management of Rifampicin-resistant Tuberculosis in South Africa (2019),including how to choose drugs,formulate treatment regimens as well as how to treat special patients, manage close contacts; and then to compare this South Africa Guidelines with the Guidelines for Drug-resistant Tuberculosis Chemotherapy in China (2019).

Key words: Tuberculosis,multidrug-resistant, Program evaluation, Guidelines, Comparative study, Comment

FENG Ying, REN Fei. Interpretation of Clinical Guidelines for the management of Rifampicin-resistant Tuberculosis in South Africa (2019) and its comparison with Guidelines for Drug-resistant Tuberculosis Chemotherapy in China (2019)[J]. Chinese Journal of Antituberculosis, 2021, 43(3): 295-298. doi: 10.3969/j.issn.1000-6621.2021.03.018

References 14

[1]	Health Department of the Republic of South Africa. Management of Rifampicnresistant Tuberculosis: A Clinical Reference Guide. Pretoria: Health Department of the Republic of South Atrica, 2019.
[2]	中国防痨协会. 耐药结核病化学治疗指南(2019年). 北京: 人民卫生出版社, 2019.
[3]	Nunn AJ, Phillips PPJ, Meredith SK, et al. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med, 2019,380(13):1201-1213. doi: 10.1056/NEJMoa1811867. doi: 10.1056/NEJMoa1811867 URL pmid: 30865791
[4]	Balabanova Y, Fiebig L, Ignatyeva O, et al. Multidrug-resis-tant TB in Eastern region of the EU: is the shorter regimen an exception or a rule? Thorax, 2017,72(9):850-852. doi: 10.1136/thoraxjnl-2016-209841. doi: 10.1136/thoraxjnl-2016-209841 URL pmid: 28209653
[5]	Barry PM, Lowenthal P, True L, et al. Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria. Am J Respir Crit Care Med, 2017,196(11):1488-1489. doi: 10.1164/rccm.201701-0013LE. doi: 10.1164/rccm.201701-0013LE URL pmid: 28665681
[6]	World Health Organization. WHO consolidated guidelines on tuberculosis. Geneva: World Health Organization, 2020.
[7]	邓国防, 张培泽, 杨敏, 等. 二线注射剂治疗耐多药结核病的现状与思考. 中国防痨杂志, 2019,41(6):604-608. doi: 10.3969/j.issn.1000-6621.2019.06.004.
[8]	Liu Q, Sun F, Li Y, et al. Practical considerations to implement the shorter regimen to MDR-TB patients in China. Clin Microbiol Infect, 2018,24(10):1035-1036. doi: 10.1016/j.cmi.2018.04.026. doi: 10.1016/j.cmi.2018.04.026 URL pmid: 29730223
[9]	Lange C, Dheda K, Chesov D, et al. Management of drug-resistant tuberculosis. Lancet, 2019,394(10202):953-966. doi: 10.1016/S0140-6736(19)31882-3. doi: 10.1016/S0140-6736(19)31882-3 URL pmid: 31526739
[10]	Harausz EP, Garcia-Prats AJ, Law S, et al. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. PLoS Med, 2018,15(7):e1002591. doi: 10.1371/journal.pmed.1002591. doi: 10.1371/journal.pmed.1002591 URL pmid: 29995958
[11]	Zhao Y, Fox T, Manning K, et al. Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retros-pective Cohort Study. Clin Infect Dis, 2019,68(9):1522-1529. doi: 10.1093/cid/ciy727. doi: 10.1093/cid/ciy727 URL pmid: 30165431
[12]	Collaborative Group for the Meta-Analysis of lndividual Patient Data in MDR-TB treatment-2017, Ahmad N, Ahuja SD, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, 2018,392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1. doi: 10.1016/S0140-6736(18)31644-1 URL pmid: 30215381
[13]	World Health Organization. Intent tuberculosis infection:Updated and consolidated guildes for programmatic management. Geneva: World Health Organization, 2019.
[14]	World Health Organization. Global tuberculosis report 2019. Geneva: World Health Organization, 2019.

[1]	MA Yan, GAO Wei-wei. Pay attention to the reasonable treatment of retreatment tuberculosis:today is not what it used to be [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 313-317.
[2]	DENG Guo-fang. Interpretation of Expert consensus on treatment and management of tuberculosis-diabetes mellitus comorbidity [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 318-321.
[3]	ZHANG Chen-chen, TAN Wei-guo, GUO Hui-xin, HUANG Xin-chun, CHEN Yan-mei, WEI Wen-jing. The effect of Mycobacterium tuberculosis infection on sputum flora structure [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 357-363.
[4]	WANG Pei, ZHAO Guo-lian, LEI Qian, ZHENG Dan, CUI Xiao-li, ZHOU Jun. Comparison of the clinical application between fluorescence PCR probe melting curve and Micropore-plate method in determining the drug resistance of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(2): 132-138.
[5]	FEI Jun, SHI Shi-yuan, HU Sheng-ping, HU De-xin, ZHANG Chen-wei. Biomechanical study of cortical bone trajectory screw in lumbar spine tuberculosis intervertebral fixation [J]. Chinese Journal of Antituberculosis, 2021, 43(2): 171-177.
[6]	LIU Wen-feng, ZHOU Lin, XU Tian-liang, YI Huai-ming, WANG Yong, WANG Qian-xin. Evaluation of the implementation effect of “mobile tuberculosis clinic” service in the prevention and control of tuberculosis in Changshan County, Zhejiang Province [J]. Chinese Journal of Antituberculosis, 2021, 43(1): 100-102.
[7]	WANG Mei-jie, LI Yu-ze, XIAO Yao, WU Ming-qi, HOU Shao-ying. A comparative study of plasma metabolomics between diabetes and diabetes complicated with pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(1): 36-41.
[8]	LI Qian, WANG Lin-bao, LUO Pei-jia, WEI Lin, LIU Yu-gang, REN Lei-peng, DING Chao. Analysis of the results of etiology and drug resistance in different surgical specimens of tuberculous empyema by two techniques [J]. Chinese Journal of Antituberculosis, 2021, 43(1): 52-57.
[9]	JIN Hong-jian. The construction of tuberculosis prevention and control service system at county level in China needs to be strengthened urgently —— Comments and suggestions of an old tuberculosis control and prevention worker [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 896-902.
[10]	ZHANG Can-you, XIA Hui, CHENG Jun. Testing and reporting requirements for Class Ⅱ biosafety cabinet in tuberculosis laboratory [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 903-909.
[11]	ZHOU Lin, LIU Er-yong, MENG Qing-lin, CHEN Ming-ting, ZHOU Xin-hua, GAO Wei-wei, LIN Ming-gui, XIE Ru-ming. Evaluation of the quality of pulmonary tuberculosis diagnosis after the implementation of the newly revised WS 288-2017 Diagnosis for pulmonary tuberculosis standards [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 910-915.
[12]	LIANG Rui-yun, FANG Wei-jun, REN Hui-li, LI Hui-ru, ZHANG Hui. Study on CT manifestations of non-tuberculous mycobacterium pulmonary disease patients with and without diabetes mellitus [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 962-967.
[13]	MA Ting-long, HAN Yi, CHENG Xu, LIU Zhi-dong. Clinical observation on treatment effectiveness of transdermal ultrasound-mediated drug delivery combined with oral anti-tuberculosis drug in patients with chest wall tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 968-972.
[14]	ZHANG Li-juan, TAO Xiao, XIA Li-li, WEI Fen-fen, ZHENG Qi. Value of clinical pathway table of enhanced recovery cluster nursing in patients with spinal tuberculosis during perioperative period [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 981-986.
[15]	LI Ai-fang, CUI Xiao-li, KANG Lei, LEI Jing, DANG Li-yun, YANG Han. Value of fluorescence PCR probe melting curve method in detecting resistance of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 998-1001.